These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3074665)

  • 1. Effects of immunosuppression with cyclosporine on beta cell function and clinical remission in very early overt type I diabetes.
    Dupre J; Stiller CR
    Adv Exp Med Biol; 1988; 246():347-55. PubMed ID: 3074665
    [No Abstract]   [Full Text] [Related]  

  • 2. [The autoimmune aspects of insulin-dependent diabetes mellitus. Immunocorrection trials in the early stages of the disease].
    Efimov AS; Poltorak VV
    Probl Endokrinol (Mosk); 1989; 35(5):85-90. PubMed ID: 2511571
    [No Abstract]   [Full Text] [Related]  

  • 3. [Type I diabetes mellitus: immunopathogenesis and chances of primary immunotherapy].
    Ziegler AG; Standl E
    Med Klin (Munich); 1987 Oct; 82(22):796-800. PubMed ID: 3316970
    [No Abstract]   [Full Text] [Related]  

  • 4. Autoimmunity to islet cells in diabetes mellitus.
    Powers AC; Eisenbarth GS
    Annu Rev Med; 1985; 36():533-44. PubMed ID: 3888064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.
    Stiller CR; Dupré J; Gent M; Jenner MR; Keown PA; Laupacis A; Martell R; Rodger NW; von Graffenried B; Wolfe BM
    Science; 1984 Mar; 223(4643):1362-7. PubMed ID: 6367043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Induction of remissions of insulin-dependent diabetes by cyclosporin].
    Feutren G; Papoz L; Assan R; Vialettes B; Pehuet M; Vexiau P; Durostu H; Rodier M; Sirmai J; Lallemand A
    C R Acad Sci III; 1986; 303(8):295-7. PubMed ID: 3094846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunosuppression with cyclosporin induces clinical remission and improved beta cell function in patients with newly diagnosed insulin-dependent diabetes. A national and international multicenter study].
    Mandrup-Poulsen TR; Mølvig JC; Andersen V; Bendtzen K; Binder C; Brøns M; d'Amore FA; Dieperink H; Enk B; Frandsen NE
    Ugeskr Laeger; 1990 Jul; 152(27):1963-9. PubMed ID: 2195734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cyclosporin A on B-cell loss in type 1 (insulin-dependent) diabetes mellitus.
    Vague P; Vialettes B; Picq R; Dol S; Lassmann-Vague V
    Diabetologia; 1989 Dec; 32(12):887. PubMed ID: 2693167
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of cyclosporine A on humoral and cellular immunity in insulin-dependent (type I) diabetes mellitus.
    Boitard C; Debray-Sachs M; Chatenoud L; Bach JF
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):193-6. PubMed ID: 3289205
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunopathogenesis and immunotherapy of type 1 diabetes mellitus].
    Pietschmann P; Schernthaner G
    Z Med Lab Diagn; 1989; 30(1):61-2. PubMed ID: 2655327
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunotherapeutic management of juvenile diabetes mellitus].
    Moncada E
    Rev Esp Fisiol; 1989; 45 Suppl():301-8. PubMed ID: 2701766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical aspects of the immunopathogenesis of type I diabetes mellitus].
    Scherbaum WA
    Internist (Berl); 1987 Apr; 28(4):228-35. PubMed ID: 3298122
    [No Abstract]   [Full Text] [Related]  

  • 13. Induction and pathophysiology of remission of insulin-dependent diabetes mellitus during administration of ciclosporin. London Diabetes Study Group.
    Dupre J; Hramiak I; Mahon JL; Stiller CR
    Horm Res; 1990; 33(2-4):152-8. PubMed ID: 2210620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Induction of remission in insulin-dependent diabetes mellitus].
    Dreval' AV; Shishko PI
    Vopr Pitan; 1991; (5):6-11. PubMed ID: 1796576
    [No Abstract]   [Full Text] [Related]  

  • 15. Probability of remission in individual in early adult insulin dependent diabetic patients. Results from the Cyclosporine Diabetes French Study Group.
    Papoz L; Lenegre F; Hors J; Assan R; Vague P; Tchobroutsky G; Passa P; Charbonnel B; Mirouze J; Feutren G
    Diabete Metab; 1990; 16(4):303-10. PubMed ID: 2265735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of predictive value of islet cell antibodies, insulin antibodies, and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients. The Canadian-European Randomized Control Trial Group.
    Mandrup-Poulsen T; Mølvig J; Andersen HU; Helqvist S; Spinas GA; Munck M
    Diabetes; 1990 Feb; 39(2):204-10. PubMed ID: 2227128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunology of type-1 diabetes. The initial stages in a causal therapy].
    Scherbaum WA; Hedderich U; Pfeiffer EF
    Dtsch Med Wochenschr; 1986 Apr; 111(15):593-6. PubMed ID: 3514198
    [No Abstract]   [Full Text] [Related]  

  • 18. Experimental models of type-I diabetes.
    Bach JF; Boitard C
    Pathol Immunopathol Res; 1986; 5(3-5):384-415. PubMed ID: 3110756
    [No Abstract]   [Full Text] [Related]  

  • 19. Type 1 diabetes: how to resist a fatal attraction.
    Roep BO
    Neth J Med; 2002 Aug; 60(7):296-7. PubMed ID: 12430578
    [No Abstract]   [Full Text] [Related]  

  • 20. Diabetes-related autoantibodies and the selection of subjects for trials of therapies to preserve pancreatic beta-cell function in recent-onset type 1 diabetes.
    Dupré J; Mahon JL
    Diabetes Care; 2000 Aug; 23(8):1057-8. PubMed ID: 10937497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.